Global cephalosporin drugs market projected to rise 3.34 percent

20 August 2019

Victoria Rees / European Pharmaceutical Review

The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.

The global cephalosporin drugs market is expected to increase at a compound annual growth rate (CAGR) of 3.34 percent in the forecast period to 2025, according to a report.

The trade of the semi-synthetic, wide-spectrum antibiotics is predicted to reach $14.1 billion by the end of the forecast period.

The research, conducted by Reportlinker, suggests that increasing incidences of pneumonia, tonsillitis, bronchitis and gonorrhoea are the main variables contributing to market growth.

Increasing R&D operations to create extremely effective and secure medicines as well as increasing the use of combination therapies further enhance the growth of the market. 

However, the growth is reportedly restricted due to the side effects of cephalosporin drugs and the development of drug-resistant bacterial strains.

Key players in the industry include Bayer AG, Teva Pharmaceuticals and GlaxoSmithKline (GSK).

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more